Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06439394 · ClinicalTrials.gov registry record
An Observational Study to Assess Optive MEGA-3 (OM3) on Dry Eye Symptoms and Quality of Life of Adult Participants With Mild to Moderate Dry Eye Disease (DED)
A clinical trial, sponsored by AbbVie.
- Completed
- Registry status
- 52
- Enrollment target
NCT06439394 is a clinical trial that has completed, run by AbbVie. The registered enrollment target is 52 participants.
The verdict
NCT06439394 has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- 52 participants
- Enrollment target
Study Summary
Dry Eye Disease (DED) is a condition where the tear film of the eye becomes unstable and along with ocular surface inflammation and damage leads to inadequate tear production and eye lubrication. This study will evaluate real-world experiences with Optive MEGA-3 (OM3) on relieving dry eye symptoms in adult participants with DED. OM3 is an over the counter (OTC) monograph drug indicated for the temporary relief of symptoms of eye dryness. Participants will administer 1 drop of OM3 on Day 1 for the acute phase of the study, then participants will administer 1-2 eye drops in each eye at least twice a day but as much as needed through Day 15. Around 50 adult participants will be enrolled at one site in the United States. There is expected to be no additional burden for participants in this trial. Study visits may be conducted on-site as per standard of care.
Interventions
- DRUG Optive MEGA-3 (OM3)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2024-06-17 |
| Est. Completion | 2024-07-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06439394
The ClinicalTrials.gov registry entry for NCT06439394 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Optive MEGA-3 (OM3) is the first listed.
NCT06439394 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06439394 about?
NCT06439394 is a clinical study titled "An Observational Study to Assess Optive MEGA-3 (OM3) on Dry Eye Symptoms and Quality of Life of Adult Participants With Mild to Moderate Dry Eye Disease (DED)". Dry Eye Disease (DED) is a condition where the tear film of the eye becomes unstable and along with ocular surface inflammation and damage leads to inadequate tear production and eye lubrication. This study will evaluate real-world experiences with Optive MEGA-3 (OM3) on relieving dry eye symptoms i...
What is the current status of trial NCT06439394?
This trial is currently completed. The enrollment target is 52 participants. The study started on 2024-06-17. Estimated completion is 2024-07-18.
What interventions are being tested in trial NCT06439394?
The interventions under investigation include: Optive MEGA-3 (OM3) (DRUG).
Who is sponsoring clinical trial NCT06439394?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.